文献速递帕金森病与运动障碍认知障碍与痴呆

临床诊断的突触核蛋白病伴帕金森综合征患者的生存率与死因:基于人群的研究

Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism: A Population-Based Study.
PubMed 文献 · JAMA Neurol · 2017-01-01

该研究基于美国明尼苏达州奥姆斯特德县1991-2010年的医疗记录链接系统,纳入461例临床诊断的突触核蛋白病伴帕金森综合征患者及452名年龄性别匹配的参照者,比较其生存率和死因。结果显示,多系统萎缩伴帕金森综合征、路易体痴呆和帕金森病痴呆患者的死亡风险显著高于参照者,而帕金森病患者的死亡风险仅轻度增加。

要点

  • 多系统萎缩伴帕金森综合征死亡风险最高(HR 10.51),路易体痴呆和帕金森病痴呆次之(HR 3.94和3.86),帕金森病最低(HR 1.75)。
  • 突触核蛋白病患者中位死亡时间比参照者早2年。
  • 患者死亡证明中最常见的死因为神经退行性疾病,而参照者最常见死因为心血管疾病。

核心结论

  • 多系统萎缩伴帕金森综合征、路易体痴呆和帕金森病痴呆患者的死亡率较一般人群显著增加,而帕金森病患者的死亡率仅轻度增加。

研究设计与样本

  • 基于人群的研究,使用罗切斯特流行病学项目医疗记录链接系统,纳入1991-2010年奥姆斯特德县461例突触核蛋白病患者和452名年龄性别匹配的参照者。

主要发现

  • 随访期间,68.6%(316例)的患者和48.7%(220例)的参照者死亡。
  • 患者中位死亡时间比参照者早2年。
  • 与参照者相比,多系统萎缩伴帕金森综合征死亡风险HR为10.51(95%CI 2.92-37.82),路易体痴呆HR为3.94(95%CI 2.61-5.94),帕金森病痴呆HR为3.86(95%CI 2.36-6.30),帕金森病HR为1.75(95%CI 1.39-2.21)。
  • 患者死亡证明中最常见的死因为神经退行性疾病,参照者最常见死因为心血管疾病。

临床怎么用

  • 临床医生可依据突触核蛋白病亚型向患者和照护者提供预后信息,并协助进行护理规划。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: To our knowledge, a comprehensive study of the survival and causes of death of persons with synucleinopathies compared with the general population has not been conducted. Understanding the long-term outcomes of these conditions may inform patients and caregivers of the expected disease duration and may help with care planning. OBJECTIVE: To compare survival rates and causes of death among patients with incident, clinically diagnosed synucleinopathies and age- and sex-matched referent participants. DESIGN, SETTING, AND PARTICIPANTS: This population-based study used the Rochester Epidemiology Project medical records-linkage system to identify all residents in Olmsted County, Minnesota, who received a diagnostic code of parkinsonism from 1991 through 2010. A movement-disorders specialist reviewed the medical records of each individual to confirm the presence of parkinsonism and determine the type of synucleinopathy. For each confirmed patient, an age- and sex-matched Olmsted County resident without parkinsonism was also identified. MAIN OUTCOMES AND MEASURES: We determined the age- and sex-adjusted risk of death for each type of synucleinopathy, the median time from diagnosis to death, and the causes of death. RESULTS: Of the 461 patients with synucleinopathies, 279 (60.5%) were men, and of the 452 referent participants, 272 (60.2%) were men. From 1991 through 2010, 461 individuals received a diagnosis of a synucleinopathy (309 [67%] of Parkinson disease, 81 [17.6%] of dementia with Lewy bodies, 55 [11.9%] of Parkinson disease dementia, and 16 [3.5%] of multiple system atrophy with parkinsonism). During follow-up, 68.6% (n = 316) of the patients with synucleinopathies and 48.7% (n = 220) of the referent participants died. Patients with any synucleinopathy died a median of 2 years earlier than referent participants. Patients with multiple system atrophy with parkinsonism (hazard ratio, 10.51; 95% CI, 2.92-37.82) had the highest risk of death compared with referent participants, followed by those with dementia with Lewy bodies (hazard ratio, 3.94; 95% CI, 2.61-5.94), Parkinson disease with dementia (hazard ratio, 3.86; 95% CI, 2.36-6.30), and Parkinson disease (hazard ratio, 1.75; 95% CI, 1.39-2.21). Neurodegenerative disease was the most frequent cause of death listed on the death certificate for patients, and cardiovascular disease was the most frequent cause of death among referent participants. CONCLUSIONS AND RELEVANCE: Individuals with multiple system atrophy with parkinsonism, dementia with Lewy bodies, and Parkinson disease dementia have increased mortality compared with the general population. The mortality among persons with Parkinson disease is only moderately increased compared with the general population.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Savica R, Grossardt BR, Bower JH, et al. Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism: A Population-Based Study. JAMA Neurol. 2017. PMID: 28505261. doi:10.1001/jamaneurol.2017.0603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。